Going Deeper on Atopic Dermatitis

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.

Satellite Symposium of the 94th Atlantic Dermatological Conference

CME/MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com

JEFFREY M.

FACULTY

FACULTY

Weinberg, MD

Associate Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai New York, New York Director, Division of Dermatology Jamaica Hospital Medical Center Richmond Hill, New York Dr. Jeffrey M. Weinberg is an associate clinical professor of dermatology at the Mount Sinai School of Medicine in New York City. In addition, he is acting director of the Division of Dermatology at Jamaica Hospital Medical Center. Dr. Weinberg graduated from the University of Pennsylvania School of Medicine in Philadelphia and completed an internship in medicine at Columbia-Presbyterian Medical Center in New York City. He then completed a residency in dermatology at the University of Pennsylvania School of Medicine.

Dr. Weinberg is a Fellow of the American Academy of Dermatology, where he has served on several committees, and a member of the Dermatology Foundation. He is a diplomate of the American Board of Dermatology.

Dr. Weinberg is on the editorial board and is a Senior Editor of Cutis. He is also an Associate Editor of the Journal of the American Academy of Dermatology.

He is a member of the Medical Board of the National Psoriasis Foundation. His clinical research encompasses a variety of dermatology-related topics, including studies of diagnostic methods in the evaluation of onychomycosis. He has been principal or co-investigator for several clinical trials. In addition, he has written or co-authored numerous articles for professional journals such as Cutis, the Journal of the American Academy of Dermatology, and Blood, as well as reviews, book chapters, and abstracts.

For additional CME activities log on to

3

LAWRENCE F. FACULTY

Eichenfield, MD

Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology University of California, San Diego, School of Medicine Chief, Pediatric and Adolescent Dermatology Rady Children’s Hospital San Diego, California Dr. Lawrence F. Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego, Vice Chair of the Department of Dermatology, and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine. He received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and Chief Resident at Children’s Hospital of Philadelphia, and completed his dermatology residency at the Hospital of the University of Pennsylvania.

Dr. Eichenfield’s clinical interests include atopic dermatitis, acne, psoriasis, vascular lesions including port wine stains and hemangiomas, neonatal dermatology, laser surgery, nevi, and skin signs of systemic disease. He has authored more than 300 journal articles, chapters, abstracts, and books on these topics and has served as the senior editor of Neonatal and Infant Dermatology, published by Elsevier, as well as The Eczemas, published by Summit Communications. He is also Editor-in-Chief of Pediatric Dermatology and serves on the editorial boards of multiple journals and periodicals.

Dr. Eichenfield was honored as a member of the Alpha Omega Alpha Medical Honor Society during medical school, as a recipient of the Benjamin Ritter Award at Children’s Hospital of Philadelphia, and as a recipient of excellence in teaching awards from UCSD Pediatrics, UCSD Dermatology, and Rady Children’s HospitalSan Diego. Named one of the “Best Doctors in America” since 1994, Dr. Eichenfield is past president of the Society of Pediatric Dermatology, past Board member of the American Academy of Dermatology as well as Chair for the upcoming 69th Annual Meeting of the American Academy of Dermatology. Dr. Eichenfield is also a founding board member of the American Acne and Rosacea Society and the founder and Co-Chair of Pediatric Dermatology Research Alliance (PeDRA).

4

MELINDA

FACULTY

Gooderham, MD, FRCPC Assistant Professor Queen’s University Kingston, Ontario, Canada Medical Director SKiN Centre for Dermatology Peterborough, Ontario, Canada

Dr. Melinda Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. A fellow of the Royal College of Physicians and Surgeons of Canada, she received her medical degree from the University of Western Ontario in 1999, and then completed her Dermatology residency at the University of Toronto in 2004. Prior to training in medicine, Dr. Gooderham obtained a Bachelor of Science from Queens University in Kingston in 1992, and a Master of Science from the University of Guelph in 1995.

Dr. Gooderham is actively involved in teaching medical students, residents, nurse practitioners, and physicians with both didactic and clinical handson teaching. She practices with a focus on psoriasis, atopic dermatitis, skin cancer, and clinical research.

For additional CME activities log on to

5

TARGET AUDIENCE

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with moderate-to-severe atopic dermatitis.

PREAMBLE

STATEMENT of NEED/PROGRAM OVERVIEW

Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and in other organ systems throughout the body.1 Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on patients, family members, and caregivers.1,2 The evolving understanding of disease pathophysiology and widespread effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management.3,4 Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression has led to new approaches to disease characterization and treatment.5,6 This Interactive Exchange™ program will open with a brief 3D-animated video highlighting mechanistic insights into atopic dermatitis development. Expert faculty will then discuss best practices in comprehensive patient evaluations, and the clinical profiles, efficacy, and safety of treatment options for moderate-to-severe disease, including biologic therapy. With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, the program will integrate clinical data and professional experience into actionable recommendations that can be used to individualize care and improve patient-clinician communication.

REFERENCES

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab.

2015:66(suppl 1):8-16.

2. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.

3. Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1.

Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.

4. Sidbury R, et al. Guidelines of care for the management of atopic dermatitis: section 3.

Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol.

2014;71(2): 327-349.

5. Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.

6. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.

6

EDUCATIONAL OBJECTIVES

PREAMBLE

After completing this activity, the participant should be better able to: •• Discuss pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, including potential treatment targets •• Evaluate patients with atopic dermatitis over time for persistent symptoms, comorbidities, and treatment responses •• Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis •• Tailor long-term therapy for moderate-to-severe atopic dermatitis to prevent exacerbations, maximize health-related quality of life, manage comorbidities, and minimize adverse events •• Educate patients and caregivers to improve their understanding of atopic dermatitis, provide Action Plans to reduce exacerbations, and promote shared decision-making

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GLOBAL CONTACT INFORMATION

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS to RECEIVE CREDIT

In order to receive credit for this activity, the participant must complete the program evaluation.

For additional CME activities log on to

7

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

PREAMBLE

DISCLOSURE of CONFLICTS of INTEREST

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Jeffrey M. Weinberg, MD Pharmaceuticals, Inc.

Grant/Research Support: Regeneron

Lawrence F. Eichenfield, MD Consultant/Independent Contractor: Anacor Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc.; Medimetriks Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.; Top MD, Inc.; Valeant Pharmaceuticals International, Inc. Grant/Research Support: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC. Melinda Gooderham, MD, FRCPC Consultant/Independent Contractor: Akros Pharma Inc.; Boehringer Ingelheim International GmbH; Eli Lilly and Company; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.; Grant/Research Support: AbbVie Inc.; Akros Pharma Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; Dermira, Inc.; Galderma SA; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Roche Laboratories, Inc.; UCB, Inc.; Honoraria: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; MedImmune, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Canada; Valeant Pharmaceuticals International, Inc.; Speakers Bureau: AbbVie Inc.; Actelion Pharmaceuticals US, Inc.; Amgen Inc.; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Sanofi Canada; Valeant Pharmaceuticals International, Inc.

8

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Ashley Marostica, RN, MSN Nothing to disclose Andrea Funk Nothing to disclose Laura Gilsdorf Nothing to disclose Rose O’Connor, PhD Nothing to disclose Jim Kappler, PhD Nothing to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For additional CME activities log on to

9

PREAMBLE

DISCLOSURE of UNLABELED USE

SLIDES

10

SLIDES

For additional CME activities log on to

11

SLIDES

12

SLIDES

For additional CME activities log on to

13

SLIDES

14

SLIDES

For additional CME activities log on to

15

SLIDES

16

SLIDES

For additional CME activities log on to

17

SLIDES

18

SLIDES

For additional CME activities log on to

19

SLIDES

20

SLIDES

For additional CME activities log on to

21

SLIDES

22

SLIDES

For additional CME activities log on to

23

GUIDELINES »» Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.

Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410183/pdf/ nihms598033.pdf

»» Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.

Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326095/pdf/ nihms598590.pdf

»» Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.

Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410179/pdf/ nihms-598620.pdf

»» Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.

RESOURCE CENTER

Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430554/pdf/ nihms685688.pdf

PATIENT RESOURCES »» International Eczema Council Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care. http://www.eczemacouncil.org

24

»» National Eczema Association The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education. http://www.nationaleczema.org

CLINICAL ASSESSMENT TOOLS »» Eczema Area and Severity Index (EASI) EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe).

Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18. http://www.homeforeczema.org/documents/easi-case-report-formfor-age-8-years-and-over.pdf

»» Investigator Global Assessment (IGA) The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials.

Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294. http://www.pubmed.gov/26685719

»» Scoring Atopic Dermatitis (SCORAD) SCORAD is a clinical tool used to assess the extent and severity of eczema.

Severity scoring of atopic dermatitis: the SCORAD index.

Consensus Report of the European Task Force on Atopic Dermatitis.

Dermatology. 1993;186(1):23-31. http://adserver.sante.univ-nantes.fr/Compute.html

RESOURCE CENTER

SUGGESTED READING »» American Academy of Dermatology 75th Annual Meeting Posters.

March 3-7, 2017. Orlando, Florida. https://www.aad.org/eposters/view/meeting.aspx?id=45

»» Management of difficult-to-treat atopic dermatitis.

Arkwright PD, et al. J Allergy Clin Immunol Pract. 2013;1(2):142-151. http://www.pubmed.gov/24565453

For additional CME activities log on to

25

»» Translating atopic dermatitis management guidelines into practice for primary care providers.

Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565. http://pediatrics.aappublications.org/content/pediatrics/136/3/554.full.pdf

»» Persistence of mild to moderate atopic dermatitis.

Margolis JS, et al. JAMA Dermatol. 2014;150(6):593-600. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352328/pdf/nihms665922.pdf

»» Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Paller AS, et al. J Am Acad Dermatol. 2016;75(3):494-503. http://www.jaad.org/article/S0190-9622(16)30330-9/pdf

»» Serious complications from Staphylococcal aureus in atopic dermatitis.

Patel D, Jahnke MN. Pediatr Dermatol. 2015;32(6):792-796. http://www.pubmed.gov/26337792

»» Anti-interleukin-31 receptor A antibody for atopic dermatitis.

Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835. https://www.ncbi.nlm.nih.gov/pubmed/?term=28249150

»» Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.

Simpson EL, et al. J Am Acad Dermatol. 2016;74(3):491-498. http://www.jaad.org/article/S0190-9622(15)02471-8/pdf

»» Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348. http://www.pubmed.gov/27690741

RESOURCE CENTER

»» Eczema and cardiovascular risk factors in 2 US adult population studies.

Silverberg JI, Greenland P. J Allergy Clin Immunol. 2015;135(3):721-728. http://www.jacionline.org/article/S0091-6749(14)01677-7/pdf

»» Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.

Silverberg JI, Silverberg NB. J Allergy Clin Immunol. 2014;133(4):1041-1047. http://www.jacionline.org/article/S0091-6749(13)01294-3/pdf

»» The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.

Whiteley J, et al. Curr Med Res Opin. 2016;32(10):1645-1651. https://www.ncbi.nlm.nih.gov/pubmed/?term=27240604

26

Please visit the CLINICAL RESOURCE CENTER for additional information and resources

www.EXCHANGECME.com/ADResources

© 2017 Global Education Group and Integritas Communications.

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.